Member Info for TorquayFan

Inan - I can't accept that 'we would be watching the post box' necessarily. The overview re. 'Focus and Progress' is quite valid IMO. However, I see the usual quicksand and agree to disagree.

Hi Ruck. 50 years at 20 billion, for ONE trillion. Maybe. Certainly many hundreds of billions. Agreed.

. . . . after your first response, exactly this went though my mind too - ''(Inan) would pick a fight if if he was the only person in the room''. And it's true. You would.

I put a REC on Ivy's post because I agree with the overview about 'focus' and progress - I have sometimes mentioned it myself. I did note that nevertheless, BoD are 'rightly excited by ALL the possibilities'. Mai pen lai.

Ray P I saw your response, '' I don't see how more resources diverted to the SCIB1 combo trial would help.'' The extra 'irons in the fire' are fantastic of course. But it's just MHO that SCIB would by now be more advanced IF all Scancell's resources over the last say 5+ years HAD been targeted at SCIB alone. It's just a thought.

Re. 'trillions' I'm not sure - one trillion being a thousand billion ? Nice day all.

You posted - ''Not really sure why you keep post REC very poorly written posts ... ''

Please Inan - I shall REC what I like . . . OK ? But I'm not sure - do you mean I should not rec. your posts ? Because I find them most helpful usually. And some others too . . .

Scancell - one day to be proven 'Masters of Cancer Vaccines' and Crumbs, 'Masters of Radar Underance'.

All good to read, well posted, nice Sunday to you and Goodnight All .

Your post rec'd - the sheer breadth of Scancell's science is mind boggling BUT Scancell need to take one product forward. I hope we will have some good news soon ?

Prof. Lindy and the BoD are no doubt rightly excited by all the possibilities - and they are trying to advance on all fronts at once.

But had Prof. Lindy NOT had that Moditope serendipity moment, for argument's sake, I'd guess SCIBs would have progressed more by now - maybe to a commercial stage. However, the IP is massively stronger with Moditope on board, but the SP glumly is not, yet.

The science will see us through - hopefully.

Ruck - you are pure mischief. The science will see us through. Take care.

C7 - nice one. The possibility of being in a 'closed period' - oh please !
I do hope so. And Balerno certainly needs cheering up.
As do I at 7.125 pence.

IMHO there won't be another US Govt. shutdown - Trump has burned his fingers on that one.
As for Brexit - that must be quite a crystal ball you are looking into - it's impossible to know how that one is going to turn out OR how it might affect Scancell . . .

Nil desperandum !

Indeed - ''Notwithstanding the result of the Award, Scancell and its collaboration partners remain committed to the ultimate objective of eliminating tumours by treating patients with such therapeutic vaccine approaches.''

And - ''Patents awarded with respect to the Moditope® platform and our on-going collaborations mean that we are now well positioned to develop Moditope® based therapeutics, such as vaccines and adoptive T-cell therapies.''

So just as you say WF. Recently Crumbs has been weaving the threads re. BioNTech / TCR / Modi 3 and it's all quite credible. But no overt news today. Just reassurance I suppose.

Wait on . . .

Crumbs 20.17 - love it !

''If you can't explain it simply, you don't understand it well enough.'' A Einstein....

Excellent

Thanks for that piece about Aduro - what a shame of course.

Seems like Aduro had the cash and Scancell have the science. Where's our deal ?

And https://www.torquayunited.com/official-tufc-tv-united-hit-7-at-plainmoor-26-01-19/

Good to see you around and ATB

Far from your statement - ''I don't think TF actually understood what the post was about ...'' I was politely asking RW about this comment about Patents - ''I would suggest they are effectively priced in more or less from the start.'' That needed more context and explanation. That's all . . .

Anyway both - keep up the good work. But I will just add that at 7.475 it seems to me that NOTHING here, of what Scancell have, including Patents, all of them, is 'priced in', from the start or even right now. ATB

I don't suppose you looked back but your explanatory post had 15 recs . . .
Keep it coming please and thanks.

Inflection points - it seems that only new trial data or monetization are likely to push the SP much higher.

As for ''muddled management and numbskull strategy'' and ''silly strategic and managerial mistakes'' - that's a very rough view of the situation - I'd hate to be around when you ARE being 'provocative'.

ATB

No need for that RW. You say it was - ''a simple and fairly obvious point''. A point obvious to the 'transmitter' is not always obvious to the 'receiver' and only the 'simple' think otherwise. In your 12.02 - ''I would suggest they are effectively priced in more or less from the start.'' That's 'from the start' BTW. But thanks for your fuller explanation of your point now.

Inan - ''Is this back to debating the inevitable as not achievable'' - no it isn't and I'm surprised at your retort. Unfortunately the 'achievable' is not 'inevitable' but as you know. I have always thought the 'achievable', highly likely.

Thanks Guys.

Patents - ''I would suggest they are effectively priced in more or less from the start.''

RW I don't see how Patents could be priced in as you say, from the start, because, until you've got 'em, you don't know you'll get 'em?

However - you can be excused for the statement - because everything (so far), about Scancell, shows that these days at least, nothing affects the SP at all, for long . . . yet . . . That's YET. GLA

Thank you so much ! ATB

Konar - can you please explain your mystery clue today . . .
I'm sure I'm not the only one interested, so if you can post - it'd be much appreciated.
Thanks and ATB

This is a few days old - CI and Vaccine combos very promising maybe but CI and CI combo - here's a hitch for BMS.

''Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.''

https://pharmaphorum.com/top-stories/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/?